Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab +/- Chemotherapy in 2nd-line ES-SCLC
NCT05901584Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in small cell lung cancer (SCLC), sponsored by Second Affiliated Hospital of Zunyi Medical University. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05901584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901584.